oral glp-1 tirzepatide Lilly orforglipron phase 3 weight loss trial Oral Tirzepatide Pill: FDA-Approved Options

Eur J Prev Cardiol 31:12601273 Hankosky ER, Wang H, Neff LM et al (2024) Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

The medication continues to improve insulin sensitivity, which can protect against the risk of developing diabetes or heart disease in the long run

Judicial Panel on Multidistrict Litigation issued a transfer order on February 2, 2024, instructing all GLP-1 stomach paralysis lawsuits involving Ozempic, Wegovy, Mounjaro and other similar GLP-1 drugs to be centralized in the U.S

As with most cosmetics, visible benefits are maintained with continued use